Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The study titled “A FIH Phase 1/2 Study to Assess Safety, To...

Regeneron Advances First-in-Human Myeloma Combo Trial, Keeping Oncology Pipeline in Focus

The latest update is out from Regeneron ( ($REGN) ). At its 2026 Annual Meeting of Shareholders held on June 12, 2026, Regeneron shareholders elect...

Regeneron Shareholders Back Directors, Auditor and Executive Pay

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The study A Randomized, Open-Label, Dose-Ranging Study to Ev...

Regeneron Tests Weekly Praluent Dosing in New Cholesterol Study: What Investors Should Watch

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The RAPID registry from Regeneron and Sanof...

RAPID Real‑World Dupixent Data Could Extend Regeneron and Sanofi’s Asthma Edge

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron’s CLIO-1 trial, officially titled “A Phase 1 Study...

Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The Phase 1, open-label study titled “A Phase 1, Open-Label,...

Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a mid-stage trial calle...

Regeneron Expands Into Pulmonary Hypertension With New Phase 2 Trial for REGN13335

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a late-stage study call...

Regeneron Targets Stroke Prevention Gap With New Atrial Fibrillation Trial

Analysts are intrested in these 5 stocks: ( ($REGN) ), ( ($CRCL) ), ( ($BURL) ), ( ($ROST) ) and ( ($PBA) ). Here is a breakdown of their recent


Regeneron, Circle, Burlington, Ross, Pembina Trending With Analysts

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN) and Merck & Company (MRK) with bull...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$609.94	+0.33%	2.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$609.94	+0.3%	2.61M
3
4
5
6

REGN

REGN

Recent News for REGN

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel